Applications
Gene editing
Gene knockout (KO) has become a cornerstone of modern life sciences, enabling researchers to investigate gene function by selectively disrupting specific genes and observing the resulting cellular phenotype.
Powered by CRISPR technology, gene KO is now widely used in functional genomics, disease modeling, target identification and validation, high-throughput screening campaigns, and cell engineering applications. By revealing how specific genes contribute to biological processes and disease, gene knockout provides critical insights that accelerate both basic research and therapeutic development.
Intracellular delivery with LumiPore®
The growing adoption of gene knockout techniques has created a demand for intracellular delivery technologies capable of efficiently introducing CRISPR-Cas9 components into a broad range of cell types while preserving cell health and functionality. The LumiPore® platform addresses this challenge through a gentle photoporation mechanism that enables efficient delivery of CRISPR-Cas9 RNPs with minimal cellular perturbation. By combining high editing efficiency with excellent cell viability and scalability across different culture formats, LumiPore supports reliable genome editing in cell lines, primary cells, and iPSC-derived models, making it a powerful tool for research, screening, and cell engineering workflows.
Resources & Protocols
To learn more about implementing gene knockout workflows with LumiPore®, including optimization strategies, troubleshooting guidelines, and application-specific recommendations, explore the white papers, application notes, FAQs, and validated protocols listed in the sections below.
| Cell line / Type | B2M | TRAC | CD52 | CD81 | CD90 | eGFP | PPARY | INSR |
|---|---|---|---|---|---|---|---|---|
| T cells naive/PBMC, unstimulated | — | — | — | — | — | |||
| Activated PBMC 3-day stimulated CD3+ | — | — | — | — | — | — | — | |
| Jurkat CD3+ | — | — | — | — | — | — | — | |
| BM-MSC adherent/suspension | — | — | — | — | — | — | — | |
| K562 | — | — | — | — | — | — | — | |
| THP-1 | — | — | — | — | — | — | — | |
| iPSC | — | — | — | — | — | — | ||
| H1299-eGFP | — | — | — | — | — | — | — | |
| Differentiated adipocytes | — | — | — | — | — | — | ||
| iPS derived microglia | — | — | — | — | — | — | — |
High-Throughput Transfection.Automation-Ready.
Seamless integration into your existing robotics workflows. No media exchange required. From R&D suspensions to clinical nanofiber structures.